Trimerised apolipoprotein A1

Drug Profile

Trimerised apolipoprotein A1

Alternative Names: Trimeric Apo A-I; Trimeric ApoA-1; Trimeric apolipoprotein A1

Latest Information Update: 01 Aug 2007

Price : $50

At a glance

  • Originator Borean Pharma
  • Class
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atherosclerosis; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 01 Aug 2007 No development reported - Preclinical for Atherosclerosis in Denmark (unspecified route)
  • 01 Aug 2007 No development reported - Preclinical for Multiple sclerosis in Denmark (unspecified route)
  • 01 Aug 2007 No development reported - Preclinical for Rheumatoid arthritis in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top